Albumin-based nanoparticles as potential controlled release drug delivery systems

Elzoghby, Ahmed O.; Samy, Wael M.; Elgindy, Nazik A.

doi:10.1016/j.jconrel.2011.07.031

Cited by 1,258 publications

(833 citation statements)

References 125 publications

Supporting

Mentioning

785

Contrasting

Unclassified

Order By: Relevance

“…[3] Despite significant research achievements, most of the current NDDSs, especially those in clinical trials or usage, e.g. drug encapsulated lipids vesicles or polymer micelles, [4] polymerdrug conjugates, and albumin-based nanoparticles, [5] mostly rely on passive targeting and generally lack the ability of active targeting. Moreover, drugs are mostly physically encapsulated or entrapped into the NDDSs, where drug release is mainly achieved via passive diffusion, making it difficult to achieve controlled release, a vital property for high therapeutic 2 efficacy.…”

mentioning

confidence: 99%

Intracellularly Degradable, Self‐Assembled Amphiphilic Block Copolycurcumin Nanoparticles for Efficient In Vivo Cancer Chemotherapy

Guo

Shen

et al. 2015

Adv Healthcare Materials

View full text Add to dashboard Cite

Chemotherapy is widely used in various cancer treatments. However, current cancer chemotherapy has a major limitation: lacking of specific targeting ability. As a result, it kills both cancerous and healthy cells, causing severe adverse side-effects and toxicity to patients which limits the dose regime and allows tumour to gain resistance. One approach to address this problem is the development of nanoscale drug delivery systems (NDDSs) which can exploit characteristic properties of tumour, such as the enhanced permeation and retention (EPR) effect, [1] and over-expressed cell-surface receptors, [2] to achieve targeted delivery. [3] Despite significant research achievements, most of the current NDDSs, especially those in clinical trials or usage, e.g. drug encapsulated lipids vesicles or polymer micelles, [4] polymerdrug conjugates, and albumin-based nanoparticles, [5] mostly rely on passive targeting and generally lack the ability of active targeting. Moreover, drugs are mostly physically encapsulated or entrapped into the NDDSs, where drug release is mainly achieved via passive diffusion, making it difficult to achieve controlled release, a vital property for high therapeutic 2 efficacy. As a result, most of the drug payloads may have been released before reaching the target sites, leading to reduced therapeutic efficacy and causing adverse side-effects.Furthermore, most NDDSs also suffer from drawbacks such as low drug loading (e.g.antibody-drug conjugates) and/or burst release (e.g. micelles/liposomes). To date, none of the current NDDSs can satisfy all of the requirements of an "idea NDDS" outlined by Langer et al. [3a] To make best use of the advantages of current NDDSs (passive and active targeting delivery to tumour) and overcome their drawbacks (unnecessary and even harmful on-way drug release before entering tumour cells and/or only a small quantity of drugs together with the nano-carriers entering tumour cells) due to the physical incorporation or encapsulation of drugs in NDDSs, which often leads to uncontrolled drug release via diffusion, we take a new approach to prepare NDDSs which is based on so-called poly(active pharmaceutical ingredient) (PAPI) strategy where the APIs are incorporated into an intracellular cleavable polymer backbone (not physically incorporated in drug carriers) in combination with selfassembly characteristics of amphiphilic block copolymers. Here PAPI is defined as a polymer prepared by polycondensation of an API or its derivative having the same or similar bioactivity as a co-or sole-monomer. Considerable advantages here are that the physicalchemical properties of the PAPIs can be readily tailored by changing co-monomers or via chemical modifications. The PAPIs can be further made into various NDDSs where the API release can be controlled via stimuli triggered polymer degradation, overcoming the drawback of un-controlled, diffusion based drug release character commonly experienced in physically incorporated systems. In principle, any drug molecules/derivatives containi...

show abstract

mentioning

confidence: 99%

Intracellularly Degradable, Self‐Assembled Amphiphilic Block Copolycurcumin Nanoparticles for Efficient In Vivo Cancer Chemotherapy

Guo

Shen

et al. 2015

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Only a few of them are currently on the market (e.g. the already mentioned Abraxane® [20] and Endorem® [65]). A few reasons are that many nanomaterials have poor drug loading efficiency (< 5%, weight of the drug respect to the nanocarrier) or too rapid a release profile after administration ("burst release").…”

Section: Discussionmentioning

confidence: 99%

“…The first type of polymers employed for the construction of nanoparticles were non-biodegradable, such as polyacrylamide or polymethylmethacrylate [19], and not applicable for administration in humans. The discovery of novel biocompatible polymers such as albumin [20] (a polyamide used to carry paclitaxel, marketed as Abraxane®), polyalkylcianoacrylate [21] (a polyanhydride), polylactateco-glycolate (PLG, a polyester that is FDA approved), solid lipid nanoparticles (SLN, produced using high-melting lipids) [22], chitosan (a hydrophilic and cationic polysaccharide obtained from crab shell) etc., opened the way for the clinical application, mostly in cancer treatment, of polymeric nanomaterials. Usually biodegradable polymers are organic macromolecules (where carbon is the main component) that contain etheroatomes (-C-O-; -C-N-; -C-S-) to facilitate degradation via hydrolysis, oxidation and bond cleavage [23].…”

Section: Polymeric Nanomaterialsmentioning

confidence: 99%

Nanotechnology Advances in Drug Delivery

Velluto¹,

Ricordi²

2017

NanoWorld J

View full text Add to dashboard Cite

Drug delivery emerged as a discipline to solve problems associated with the majority of the current drugs, such as poor water solubility, poor physical stability, poor absorption and side effects. Large pharmaceutical companies are investing in drug delivery technologies to find better ways to administer existing drugs rather than designing new products. The secret to a successful drug delivery system, one that allows controlled release over a prolonged period of time, is in the carrier. An ideal drug carrier must be biocompatible, biodegradable, water friendly, selective, easy to prepare, stable, cheap, and finally, ultra-small. Therefore, the interdisciplinary field of nanotechnology and nanomaterials is playing a big role in drug delivery by providing new tools to develop ideal nanocarriers and find appropriate solutions for medical problems. In this review, we briefly recapitulate the history of nanomaterials in drug delivery, explore their unique properties, and report an example of the design and development of polymerbased nanomaterials. We also revisit the most challenging applications of drug delivery for cancer treatment, cell and tissue transplantations and stem cell therapies. Overall, nanotechnology-based drug delivery systems administered by different routes can be considered promising tools to improve patient compliance and achieve better therapeutic outcomes in critical illnesses.

show abstract

“…The main stabilizing function of fetal calf serum was believed to be ascribed to the presence of a variety of serum proteins, including bovine serum albumin (BSA), which has been widely used to prepare drug nanoparticles. The way in which BSA or HAS (human serum albumin) stabilize nanoparticles has been reported and reviewed (Kratz, 2008;Elzoghby et al, 2012).…”

Section: Preparation Methodsmentioning

confidence: 99%

A nanoparticulate drug-delivery system for glaucocalyxin A: formulation, characterization, increased in vitro, and vivo antitumor activity

Han

Guo

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

Glaucocalyxin A (GLA) is a phytochemical component with multiple pharmacological activities; however, glaucocalyxin A's wider use has been restricted by its poor solubility. In this study, GLA nanosuspensions were prepared with precipitation-combined ultrasonication and were characterized by dynamic light scattering (DLS), transmission electron microscope (TEM), and differential scanning calorimetry (DSC). The GLA nanosuspensions were spherical with a smooth surface and a small size of 143 nm, the drug payload achieved 8.95%, and the maximum GLA concentration reached 1 mg/mL. The lyophilized powders for the GLA nanosuspensions were amorphous and displayed a biphasic drug release pattern with an initial burst release and a consequent sustained release. In contrast to the free drug solution, GLA nanosuspensions showed higher in vitro antitumor activity against HepG2 cells (IC 50 value of 1.793 versus 2.884 mg/mL at 24 h, p50.01). Meanwhile, nanosuspensions displayed better anticancer efficacy than free GLA on H22 bearing mice (54.11% versus 36.02% tumor inhibition rate). These results indicate that GLA nanosuspensions have great potential for the treatment of hepatic cancer. KeywordsCharacterization, Glaucocalyxin A nanosuspensions, in vitro antitumor efficacy, in vivo antitumor efficacy, preparation History

show abstract

Albumin-based nanoparticles as potential controlled release drug delivery systems

Cited by 1,258 publications

References 125 publications

Intracellularly Degradable, Self‐Assembled Amphiphilic Block Copolycurcumin Nanoparticles for Efficient In Vivo Cancer Chemotherapy

Intracellularly Degradable, Self‐Assembled Amphiphilic Block Copolycurcumin Nanoparticles for Efficient In Vivo Cancer Chemotherapy

Nanotechnology Advances in Drug Delivery

A nanoparticulate drug-delivery system for glaucocalyxin A: formulation, characterization, increased in vitro, and vivo antitumor activity

Contact Info

Product

Resources

About